PTCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PTC Therapeutics Inc (PTCT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, positive hedge fund activity, and technical indicators suggesting bullish momentum. Despite a decline in revenue, the company is improving its net income and EPS, showing potential for long-term growth.
The stock is showing bullish momentum with MACD positively expanding, RSI neutral at 55.57, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The pre-market price is $67.89, up 1.33%, and is trading above the pivot level of 66.363, with resistance levels at 68.359 and 69.592.
Analysts have raised price targets recently, with Barclays setting a high target of $120 and maintaining an Overweight rating.
Hedge funds are significantly increasing their positions, with a 3181.08% increase in buying activity.
The addition of Jessica Chutter to the Board of Directors brings extensive biotechnology investment banking experience, which could support strategic growth.
Revenue dropped by 22.75% YoY in Q4 2025, indicating potential challenges in sales.
Gross margin slightly declined by 0.78% YoY, which may indicate cost pressures.
In Q4 2025, revenue dropped to $164.68M (-22.75% YoY), but net income improved significantly to -$134.97M (+104.85% YoY). EPS also improved to -1.64 (+92.94% YoY), showing progress in cost management despite revenue challenges.
Analysts are broadly positive on PTCT, with multiple firms raising price targets and maintaining Overweight or Buy ratings. Barclays sees significant upside potential, citing underappreciated opportunities in phenylketonuria and a favorable biotech industry outlook.
